← Back to Search

Behavioural Intervention

Gamified Intervention for Alzheimer's Disease

N/A
Waitlist Available
Led By Stuart Zola
Research Sponsored by MapHabit, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-post: the assessment was administered at the beginning and end of the study's duration (6-month study).
Awards & highlights

Summary

This trial tests a special software called MapHabit that includes game-like features and virtual reality to help people with mild to moderate Alzheimer's or related dementias stay engaged and remember things better. It aims to improve their quality of life and reduce the burden on their caregivers.

Eligible Conditions
  • Alzheimer's Disease
  • Dementia
  • Gamification
  • Assistive Technology

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-post: the assessment was administered at the beginning and end of the study's duration (6-month study).
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-post: the assessment was administered at the beginning and end of the study's duration (6-month study). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) from baseline at 6 months
Change in Margaret Blenkner Research Center (MBRC) Caregiver Strain instrument from baseline at 6 months
Change in User Interaction and Engagement from baseline at 6 months
+1 more
Secondary study objectives
2-item Satisfaction Scale (SS-2)

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Gamified InterventionExperimental Treatment1 Intervention
This condition will involve the implementation of an assistive technology software (named the MapHabit system) with added gamification features into the daily care of individuals with mild to moderate stage of dementia. The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application will be made available to families through compatible tablets.
Group II: Exploratory InterventionExperimental Treatment1 Intervention
The exploratory condition will be given the same MHS version as the active comparator (control condition). However, for this group, participants will also engage in virtual reality games throughout the duration of the study. These virtual reality games are integrated with the MHS and includes cognitive games revolving around mental acuity, motor skills, etc.
Group III: Non-gamified InterventionActive Control1 Intervention
This control condition acted as the active comparator to the experimental condition. The same assistive technology, the MapHabit system, will be given to a separate group of participants. The difference here will be that the software will be a version that does not include gamification features.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
The MapHabit system
2022
N/A
~50

Find a Location

Who is running the clinical trial?

MapHabit, Inc.Lead Sponsor
3 Previous Clinical Trials
92 Total Patients Enrolled
VirtuleapUNKNOWN
Stuart ZolaPrincipal InvestigatorMapHabit, Inc.
1 Previous Clinical Trials
50 Total Patients Enrolled

Media Library

The MapHabit system (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05422339 — N/A
Alzheimer's Disease Research Study Groups: Non-gamified Intervention, Gamified Intervention, Exploratory Intervention
Alzheimer's Disease Clinical Trial 2023: The MapHabit system Highlights & Side Effects. Trial Name: NCT05422339 — N/A
The MapHabit system (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05422339 — N/A
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top